Superworth

Lineage Cell Therapeutics price to sales ratio LCTX

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026
19.3×
10-year median
28.1×
Against its 10-year history
20th
percentile: 0 is its lowest day, 100 its highest
10-year range
9.9× to 166×
Peer median
3.6×

Lineage Cell Therapeutics' price to sales ratio is 19.3× as of Oct 23, 2026.

That is below its ten-year median of 28.1×, lower than on 80% of days in the last ten years.

Over that time it ranged from 9.9× in Apr 2025 to 166× in Feb 2021.

The median for 4 biotech stocks of a similar size is 3.6×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.3×17.4×40.9×
202535.1×9.9×40.2×
202410.8×10.8×31.2×
202321.7×14.9×23.9×
202214.3×13.3×94.6×
2021117×95.1×166×
202097.3×30.7×97.3×
201938.0×28.4×51.8×
2018n/m a value too high to mean anything
201754.6×47.3×63.2×
201659.3×27.4×62.4×
201552.2×33.7×90.7×
201459.8×34.2×73.7×
201363.0×51.9×71.2×

Against its peers

Companies in Biotechnology nearest Lineage Cell Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
LCTXLineage Cell Therapeutics19.3×
PLXProtalix BioTherapeutics2.5×
MGTXMeiraGTx2.2×
VCELVericel7.1×
ADMAAdma Biologics4.7×
Peer median3.6×

Where Lineage Cell Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lineage Cell Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.